Mazhar 2007.
| Methods | Cross‐over RCT Power analysis: not presented |
|
| Participants | Location: Huddersfield, England 11 participants,19 asthma participants were also included and reported separately Baseline characteristics: reported to be comparable but not specified Setting: ward COPD definition: not reported Exclusion criteria: respiratory failure |
|
| Interventions | On the 2nd and 4th day of admission, regular terbutaline dose was replaced by a salbutamol study dose. Five 100 µg salbutamol doses were inhaled from a metered dose inhaler plus spacer (pMDI + SP) or 5 mg was nebulised (NEB) Beta2 ‐agonist: salbutamol pMDI: Ventolin Evohaler; GlaxoSmithKline, Brentford, UK Spacer: Volumatic (GlaxoSmithKline) large volume spacer Nebuliser: Sidestream chamber (Respironics, Tangmere, UK) Dosage ratio spacer/nebuliser: 1:10 Co‐interventions: terbutaline, other were not reported Medication adherence rates: not reported |
|
| Outcomes | Urinary salbutamol excretion, change in FEV1 Time points: 30 min and 24 h (salbutamol excretion) and baseline and after 1 hour for FEV1 |
|
| Notes | Source of funding not reported | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Unclear risk | Quotation: "The inhalation method to be used on the study days was randomized." Randomisation protocol not described |
| Allocation concealment (selection bias) | High risk | Randomisation protocol not described Comment: Given probable lack of blinding, this also probably not done |
| Blinding of participants and personnel (performance bias) All outcomes | High risk | Blinding or the use of placebo was not described in the manuscript. Comment: probably not done |
| Blinding of outcome assessment (detection bias) All outcomes | High risk | Blinding or the use of placebo was not described in the manuscript. Comment: probably not done |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Comment: none detected |
| Selective reporting (reporting bias) | Low risk | Comment: none detected |
| Other bias | Low risk | No data provided regarding possible sequence effect in cross‐over trial |